NCT05737602View on ClinicalTrials.gov

Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease

NAEnrolling by invitationINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

July 1, 2026

Conditions
Von Hippel-Lindau DiseaseGenetic Disorder
Interventions
BEHAVIORAL

3RP-VHL

An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals with VHL.

Trial Locations (1)

02215

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
collaborator

The Rappaport Foundation

UNKNOWN

collaborator

The Claflin Distinguished Scholar Awards

UNKNOWN

lead

Massachusetts General Hospital

OTHER